News | July 08, 2025
Everest Medicines progresses in AI-powered mRNA platform at 2025 R&D day
The company showcased three core programs developed through this platform
The company showcased three core programs developed through this platform
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Subscribe To Our Newsletter & Stay Updated
